ArticleMolecular therapy. Oncology2025
Characterization of a multiplex digital PCR assay to quantify total T cells relative to chimeric antigen receptor-positive T cells.
Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor-T cells (CAR-T) have become a widely utilized therapy for B cell malignancies and are under investigation in early-phase clinical trials for a host of other hematologic and solid malignancies. Monitoring of CAR-T persistence has largely relied on quantitative PCR, flow cytometry, or a combination of these methodologies. Digital PCR (dPCR) has gained favor as a sensitive and user-friendly method for monitoring CAR-T persistence in patients after infusion and can be adapted to any CAR-T construct. Historically, CAR-T quantitation has been expressed in copies per microliter (copies/μL) or as a percentage of total nucleated cells, both of which fail to provide information on the broader immunologic context for the patient. We have developed a T cell-specific dPCR assay that can be multiplexed with CAR-T and control gene assays to provide quantitation of total T cells as well as CAR-T and total nucleated cells. This assay eliminates the need for redundant quantitation of T cells by flow cytometry and in combination with ultra-sensitive CAR-T assays can allow a greater depth of CAR-T quantitation relative to total T cells with minimal source sample needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.